Vistagen therapeutics reports new preclinical mechanism of action data supporting ph94b's potential anti-anxiety activity via peripheral nasal neurons without entry into the brain

Preclinical study of intranasal radiolabeled ph94b in laboratory rats further differentiates ph94b's mechanism of action from benzodiazepines preclinical study of intranasal radiolabeled ph94b in laboratory rats further differentiates ph94b's mechanism of action from benzodiazepines
VTGN Ratings Summary
VTGN Quant Ranking